Forensic Science

Community information
Join the BrightTALK forensic science community for access to online forensics training from respected professionals in the field. Study forensic science online to learn necessary skills for trace evidence in forensics, liquid and gas chromatography and sample preparation. You can also attend live webinars to interact with forensic scientists and have your questions answered.
  • This webinar will focus on operations and maintenance of the StatSpin Express 3 centrifuge. By performing simple inspections, routine maintenance and operating the centrifuges as described in this webinar, you can maximize your StatSpin Express 3 uptime and sustain your productivity.
  • RNAi screening has made it possible to identify new genes, or gene networks, that are involved in a wide vari¬ety of biological processes, including assays relevant to signal transduction, cell viability, cell morphology, protein localization and function, drug resistance, and responses of host cells to pathogens. As such, RNAi continues to help us gain critical insights into the mechanisms underlying human disease and accelerate the development of treatments for cancer and a host of other disorders. The intersection between RNAi screening and complementary approaches such as CRISPR-Cas9-mediated genome editing has opened up new opportunities for assay development, screening and validation. The successful implementation of genome-editing technologies in several species suggests this will serve as an important and relevant tool for validation studies in numerous cell lines and model systems. Additionally, RNAi rescue experiments using LentiORFs serve an important role in further validating and boosting confidence of screened hits. As we continue to develop new strategies to improve genome-wide RNAi screening and validation, the significance of RNAi as a research tool will remain for many years to come.
  • Computer Aided Synthetic Design: How ARChem Can Improve Your Efficiency and Creativity

    Are you looking for a better way to synthesize a target molecule?

    Have you hit a roadblock in the lab or need an extra burst of creative thinking?

    Join Orr Ravitz at 10:00 AM (EDT) on July 16th for an overview of the future of synthetic design and the software that can help improve your efficiency and creativity in the lab with ARChem.

    He will discuss how medicinal chemists, process chemists and material scientists use ARChem as an idea generator – a tool for route scouting, for brain storming sessions, for the daily synthesis planning and potentially provide an alternative that gets you to curated experimental pathways faster than exploring the literature.

    This webinar will cover:

    ◦The technology behind ARChem and real life case studies
    ◦How ARChem can improve your productivity and creativity in the lab
    ◦Future developments of our synthetic design software
  • RNAi screening has made it possible to identify new genes, or gene networks, that are involved in a wide vari¬ety of biological processes, including assays relevant to signal transduction, cell viability, cell morphology, protein localization and function, drug resistance, and responses of host cells to pathogens. As such, RNAi continues to help us gain critical insights into the mechanisms underlying human disease and accelerate the development of treatments for cancer and a host of other disorders. The intersection between RNAi screening and complementary approaches such as CRISPR-Cas9-mediated genome editing has opened up new opportunities for assay development, screening and validation. The successful implementation of genome-editing technologies in several species suggests this will serve as an important and relevant tool for validation studies in numerous cell lines and model systems. Additionally, RNAi rescue experiments using LentiORFs serve an important role in further validating and boosting confidence of screened hits. As we continue to develop new strategies to improve genome-wide RNAi screening and validation, the significance of RNAi as a research tool will remain for many years to come.
  • Understanding your customers is fundamental to effective communication. Current segmentation strategies draw on ever more detailed information about how patients, physicians and payers behave through the use of open source, social media and real world data. However, segmentation still lacks clear insight into why these stakeholders behave as they do – and therefore how best to change their behaviour.
    Working with behavioural change experts Hamell, this one hour live discussion will look at why current segmentation strategies are failing, and the importance of understanding what drives patient or customer behaviour. Using case studies, speakers will explore how segmenting by behavioural drivers can create advanced, effective strategies to change patient, customer and payer behaviour.
    This event will focus on three key areas:

    •The theory behind behavioural segmentation and how it challenges the status quo
    •Benefits of behavioural segmentation communication strategies and the problems answered by behavioural segmentation strategies
    •Behavioural segmentation in action: practical application of this approach
  • Life sciences companies need to make better use of the insights that real world data (RWD) can provide in order to improve market access, sales and market growth strategies – and ultimately to improve the applicability of new and existing therapeutics for patients. Insights come not just from the multiple sources of RWD available, but from advanced analytics that highlight the effectiveness of a treatment by geographic area, and link healthcare providers, institutions and patients to relevant and meaningful outcomes.

    This one-hour event will take a hands-on approach – detailing how insights derived from RWD (and collaboratively with other sources) are enabling all elements of the life science industry to do things better.

    Insights experts Robin Munro and Christian Marcazzo will deliver case studies on how RWD can help life science companies in:

    Sales and Marketing – incorporate RWD and evidence into segmentation, targeting, and engagement of physicians and institutions
    Commercial Effectiveness – measure commercial campaigns, and demonstrate the impact to the healthcare system
    Medical Affairs – find and engage medical education prospects and target appropriate healthcare authorities, healthcare professionals and payers, to improve quality of care and outcomes
    Public Affairs and Market Access – develop qualitative and quantitative insights to design education, advocacy and access-related campaigns within the healthcare ecosystem

    The event will also give an exclusive look at what can be achieved from combining data sources – using Diabetes in England as a case study, Zephyr has implemented novel methods to demonstrate an evidence-based approach to improving information sharing within sales teams and to engaging accounts and payers. We explore how patient outcomes from RWD can add value to commercial strategy.
  • Cell lines remain the workhorses of laboratory research, both in academic and industrial settings. This webinar will focus on best practice in selecting and maintaining cell lines for research, to ensure research outputs are relevant and reproducible. Features of cell lines that might be used in selection will be discussed. This will include monolayer or suspension culture; passage number; doubling time; immortalisation; karyotype; receptors; expression profiling and use of bioinformatics tools like the cancer cell line encyclopaedia. Using breast cancer as an exemplar, I will discuss more specifically how to choose the most relevant cell line model to address a particular research question. Finally I will describe how to use (and access) human material to help develop more clinically relevant cell culture systems to model human disease and the role that biobanks play in this process.
  • Cell lines remain the workhorses of laboratory research, both in academic and industrial settings. This webinar will focus on best practice in selecting and maintaining cell lines for research, to ensure research outputs are relevant and reproducible. Features of cell lines that might be used in selection will be discussed. This will include monolayer or suspension culture; passage number; doubling time; immortalisation; karyotype; receptors; expression profiling and use of bioinformatics tools like the cancer cell line encyclopaedia. Using breast cancer as an exemplar, I will discuss more specifically how to choose the most relevant cell line model to address a particular research question. Finally I will describe how to use (and access) human material to help develop more clinically relevant cell culture systems to model human disease and the role that biobanks play in this process.
  • The way that physicians want and need to consume information is changing, almost to the point of being unrecognisable from the tried and tested methods of yesteryear, Working in conjunction with Ashfield Healthcare this event brings together Medical Futurist Dr Bertalan Meskó, Dr Partha Kar, Consultant Endocrinologist, Portsmouth Hospitals NHS Trust, with Ruth Herman and Nigel Campbell of Ashfield, which recently launched the Medical Education Future Forum and will be presenting insights from this unique programme.

    Taking place on the 21st May at 12.30 (UK), 13.30 (EU), 07.30 (E. US) and moderated by pharmaphorum's CEO Paul Tunnah, the debate will centre on three key questions,

    Why and how are physicians changing the way they receive information?
    What are the trends and technologies shaping the landscape of medical communication?
    What are the implications of this for pharma (with examples)?
  • Improve Your Mass Spectrometry Workflows With the New NIST Software, Featuring the Wiley 10th/NIST 2014

    Hosted by Prof David Sparkman

    Release 2.2 is one of the most significant improvements in NIST’s MS Search software. Prof Sparkman will lead an online webinar providing insight into the latest improvements in the most popular mass spectrometry program on the planet, with insights into how you can improve and speed up your analyses by using the full suite of functions available in MS Search 2.2 and the power of using these with the broadest compound coverage available.
    -Compatibility and systems interface tips
    -Retention time workflow
    -LCMSn workflow
    -Accurate mass workflow
    -Search strategies
    -Compound coverage strategies
  • Regardless of the colour of the next UK government that emerges as a result of the May election, the £30-£50bn NHS budget chasm is the abyss that all the parties fear in respect of its thereat to quality health service delivery and re-election.

    With political backs to the abyss, no hostages will be taken. It is not unrealistic to expect a well co-ordinated and concerted offence by politicians and patient organisations alike on industry pricing of innovative speciality and rare diseases medicines:

    With this scenario in mind pharmaphorum is once again working with IMS Health to bring you expert insight into what this means for the UK health system and more specifically market access for specialist treatments in the post-election environment.

    Angela McFarlane, Senior principal IMS Health Local Market Access, Anthony Grosso, Principal Pharmacist at the National Hospital for Neurology and Neurosurgery and Sheela Upadhyaya, previously a NHS Senior Manager with over 17 years of experience in the delivery of services and in commissioning of highly specialised services for rare and ultra rare conditions, combine with pharmaphorum's Paul Tunnah to deliver an accurate analysis and frontline insight as to the already complex roadmap for access is about to change again.

    This one hour event will include analysis of informed predictions which include:

    The NICE HTA criteria will get tougher post end to end review (IMMTreV)
    NICE and the NHS England will join forces to streamline access pre/post NICE
    Risk at local level will be shifted to Providers under the new marginal tariff arrangements; which could indeed see a close to the CDF as the PbR excluded drugs list becomes a thing of a glorious past
    Provider baselines will take the strain of innovation - the tough decisions will be softened by a drive to really accelerate uptake of NICE approved medicines

    How can industry prepare for these changes in what is already a tough and complex environment?
  • How do ischemia and fixation impact the quality of your assay results and information transfer? Garbage in! Garbage out! Join Geoffrey Baird MD, PhD and David Chafin, PhD at 9 AM Mountain Time, March 31, 2015, who will discuss the impact of ischemia and fixation on assay results, information transfer and some novel approaches to address these important factors. Dr. Baird is an Assistant Professor of Laboratory Medicine and an Adjunct Assistant Professor of Pathology at the University of Washington. Dr. Chafin is a Principle Scientist, Technology and Applied Research at Ventana Medical Systems Inc.
  • How can ischemia impact your assay results? Watch this video and see...
  • This session provides a local Trust perspective on how the Industry Costing Template can be practically embedded for financial management of commercial research studies.

    A brief overview of the national tool principles is provided, but the main focus of the session is on practical examples of how these principles have been locally developed and implemented to support investigator and directorate incentivisation to encourage involvement in commercial contract studies.

    Who should view this session?

    "Financial Management of Commercial Contract Studies: A Trust perspective" is a must see for all NHS staff supporting commercial research including R&D and Finance teams, as well as Local Clinical Research Network staff supporting Trusts in their area to conduct commercial contract research.
  • As part of the Network's HSJ award category sponsorship, Danetre Medical Practice were highly commended for the entry to Clinical Research Impact.

    Jo Gilford, Practice managing partner, and Laura Hopwood, research nurse, discuss their story and how the practice turned research into core business.

    The presentation covers:

    * Their vision for research in the practice
    * Actions and best practice in creating a research culture
    * Outcomes - how the research portfolio has increased by 500% to date since undertaking these actions
  • COPD is a widespread, costly and largely preventable condition which affects over 300 million people worldwide and is recognised as the ‘third-leading’ cause of death in most countries. Adherence rates among patients with the condition are seen to be low, despite evidence that shows appropriate use of medication and sensible lifestyle changes can reduce mortality by 60% and hospital admissions by as much as 42%.

    Given the proven increase in quality of life when adherence occurs, and yet the persistence of non-adherence globally, there is clearly a disconnect. So why is poor self-management so prevalent and what can we do about it?

    In conjunction with self-management and behavioural change specialists Atlantis Healthcare, we present a multi-stakeholder webinar and debate, which will combine real world patient needs with expertise from healthcare, pharma and patient advocates to look at the challenges to successful self-management/adherence and ascertain what the industry can do to better support patients in achieving optimum outcomes.

    The webinar is comprised of 15 minutes of presentation and 40 minutes of live debate - which you can participate in, sending questions to the panel.

    A live tweetchat (#rwCOPD) will follow the webinar, enabling full interaction across all stakeholders to further delve into this topic and explore some of the issues and solutions raised during the webcast.

    This is the second webinar within the Patient Insights Summarized series.

    Your panel for this event is:

    Ana-maria Arboleda, Managing Director, Atlantis Healthcare Spain
    Dr Joan Escarrabill, Director of the Master Plan for Respiratory Diseases, Ministry of Health (Catalonia)
    Prof. John Weinman, Head of Health Psychology, Atlantis Healthcare
    Rolf Taylor, ‎Senior Director, Corporate Development, COPD Foundation
    Paul Tunnah (Moderator), CEO, pharmaphorum
  • This session gives an overview of the support available from the NIHR Clinical Research Network life-sciences industry team at a local and National level and explains how the network works in partnership with you to ensure your study is set up rapidly and recruits to time and target.

    Guidance on communication routes and our query resolution pathway is included.

    The webinar will also look at up to date performance data, how we collect it and how this information is transformed to ensure studies and sites are actively managed to deliver.

    Who should view this session?

    "Getting the best from the Network" is a must see for any CRA, Start up manager, study manager or NHS R&D manager who is involved in setting up and managing commercial contract clinical research in the NHS.
  • The truth about delivering clinical research in the UK

    - Are you looking to deliver your research within Europe?
    - Need multiple, reliable sites?
    - Do you want to know why you should come to the UK?

    In the past the UK’s reputation for delivering clinical research was questionable. But that’s all changed. Over the last six years the research landscape here has changed dramatically allowing us to make great strides in delivering research for the life-sciences industry. So whether you’re a small CRO, a medium med tech, or a pharma giant - we can help you.

    The National Institute for Health Research (NIHR) Clinical Research Network* (see below) is hosting a live webinar which will explode common myths around the UK’s ability to deliver commercial clinical research. This session will be hosted by Matt Cooper, Life-sciences Development Director. It will include performance data that will demonstrate why the UK should be your first choice for clinical research. You can find out:

    - How much the UK’s market volume of commercial contract research (supported by the NIHR CRN) has changed
    - What percentage of the UK’s National Health Service (NHS) is actively delivering commercial contract research studies (with support from the NIHR CRN)
    - On average how many days it takes for NHS sites to get regulatory approval for research to take place (with NIHR CRN support)
    - What percentage of commercial contract studies (supported by the NIHR CRN) are delivered to time and target
    - How we are keeping clinical research in the public eye
    - How the UK is sharpening its competitive edge by achieving more and more key first global patient milestones
  • With the advent of NGS and existing molecular approaches, why is IHC unique and relevant for companion diagnostics? January 22, 2015 to learn more from Dr. Mary Padilla, Pathologist, Senior Medical Director, Companion Diagnostics, Ventana Medical Systems Inc. If you provide companion diagnostic services, develop targeted therapies, or prescribe targeted therapies, then this is the webinar for you!
  • With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what is next, what are the ramifications for high priced/innovative treatments delivering beneficial outcomes to defined patient populations in the UK and how can pharma navigate seemingly choppy waters of access for rare disease treatments and orphan drugs?

    Working in partnership with IMS Health, pharmaphorum has assembled an expert panel including NHS England’s Malcolm Qualie, Alan Kane of Shire Pharmaceuticals, Angela McFarlane of IMS Health, the Cystic Fibrosis Trust's Nick Medhurst and pharmaphorum’s own Paul Tunnah to present and debate around these issues in a free to attend one hour webinar.

    This event will cover:
    • Access, in the UK, to higher priced drugs/innovative treatments
    • Rare Disease/Orphan Drug access in the UK
    • The evolution of the Cancer Drugs Fund - what does this look like, what could it mean for pharma/healthcare

    It will also enable frank discussion around the new NHS England processes.
  • Continuing concerns exist in the clinical laboratory community about the appropriate methodologies for satisfying requirements for calibration verification and linearity testing.

    During his presentation, Dr. Jack Zakowski will discuss issues associated with these regulatory requirements and will outline approaches to satisfy them.
  • Key Topics:

    *Insight:
    What is your multichannel maturity vs industry average and vs best-practices in leading industries?

    *Innovation:
    What’s your 3-year strategy for the customer-centric New Normal?

    *Integrated execution:
    How do you set up an agile internal network to deliver a consistently great customer experience?

    *Impact:
    How do you assess whether you are moving in the right direction?
  • In this presentation we will re-visit an often overlooked parameter in the CBC, the MPV. This parameter has critical clinical applications, such as discriminating between thrombocytopenias caused by bone marrow disease (low platelet production) versus those caused by increased platelet destruction in the circulation.
  • - Are you working for a Contract Research Organisation (CRO)?
    - Are you looking to place your research within the UK?
    - Do you want to know how the CRN can help deliver your study?

    In the past the UK’s reputation for delivering clinical research was questionable. But that’s all changed. Over the last six years the research landscape here has changed dramatically allowing us to make great strides in delivering commercial contract research.

    The National Institute for Health Research (NIHR) Clinical Research Network is hosting a live webinar which will explain how we work together with CROs to meet the needs of the life-sciences industry. Not only will we explode common myths around the UK’s ability to deliver commercial contract research, we will also use performance data to demonstrate why the UK should be your first choice for clinical research delivery.

    This session will be hosted by Dr Matt Cooper, Life-sciences Development Director, of the NIHR Clinical Research Network. It will include:

    - An explanation of how CROs fit into the UK’s research delivery infrastructure
    - A look at the UK’s market volume of commercial contract research
    - The percentage of the UK’s National Health Service (NHS) that is actively delivering commercial contract research studies with our support
    - Downward trends in time taken for NHS sites to get regulatory approval for research to take place
    - The proportion of commercial contract studies that we are delivering to time and target
    - How we are keeping clinical research in the public eye
    - Information on data tools that are helping to UK to gain ground in research delivery
    - How the UK is sharpening its competitive edge by achieving more and more key first global patient milestones
  • Wébinaire présenté par Sigma Aldrich:
    Audits Inopinés: Etes vous prêts?
    - Comment les préparer avec vos fournisseurs
    - Les connaissez vous vraiment
    - Savez vous comment ils se préparent
    - Etes vous prêts
    Afin de prévenir de possibles pratiques frauduleuses dans la fabrication de dispositifs médicaux, la Commission Européenne a publié la Recommandation 2013/473 / EU sur les audits et évaluations réalisés par les organismes notifiés, dans le cadre de la mise en oeuvre des Mesures d'action immédiate post- PIP.
    Un des changement important introduit par cette recommandation concerne les audits inopinés des sous-traitants déterminants et fournisseurs essentiels de matières premières. Les auditeurs des organismes notifiés peuvent auditer leur site de fabrication au même titre que le fabricant du dispositif médical.
    Le chiffre de 5000 audits inopinés est avancé par les organismes notifiés pour cette année, en plus des audits de surveillance et de certification classiques. Ils sont en premier lieu prévus sur les sites des fabricants de dispositifs médicaux, et peuvent désormais être étendus aux sous-traitants et fournisseurs.
    C'est le moment d'évaluer le système qualité et la chaine d'approvisionnement des fournisseurs de vos matières premières critiques. Nous vous invitons à vous joindre à notre wébinaire "Audits Inopinés: Etes vous prêts?" dans lequel nous parlerons des implications de cette Recommandation sur les relations avec les fournisseurs et comment s'y préparer:
    Les sujets abordés:
    - qu'est ce qu'un audit inopinés et quel est son périmètre d'évaluation
    - que recherchent les organismes notifiés pendant un audit inopiné
    - quelle est la définition d'un fournisseur essentiel
    - les questions à poser aux fournisseurs de matières premières critiques pour se préparer
  • The latest technology solving problems in your laboratory.
    Automatically. The webinar will cover:
    - Introduction to Automated Intelligent Morphology
    - Performance of the DxH AIM technology in real-life examples
    - Case studies showing AIM at work
  • Webinar presentado por Sigma-Aldrich:
    Las auditorías sin previo aviso: ¿Está usted listo?
    Cómo prepararse y Qué preguntar a sus proveedores
    ¿Las conoce?.
    ¿Sabe cómo las realizan?.
    ¿Está usted preparado?
    En un esfuerzo por impedir las prácticas fraudulentas en la fabricación de dispositivos médicos, la Comisión Europea publicó la recomendación (2013/473 / UE) centrándose en las prácticas de evaluación y auditoría de los organismos notificadores en el campo de los dispositivos médicos.
    Hay una especial atención y preocupación por las auditorías sin previo aviso. Éstas, que no son anunciadas, son evaluaciones adicionales de los organismos competentes a los fabricantes y/o proveedores de las materias críticas. Los auditores encargados por el organismo notificador podrán auditar sin previo aviso sus instalaciones o fábricas y proceder a su inspección. Más de 5.000 auditorías sin previo aviso se esperan para este año y se suman a las auditorías de vigilancia y de renovación de ciclos de certificación por tres años.
    Es el momento para asegurarse que los sistemas de gestión de la calidad y la cadena de suministro de su proveedor están correctamente y tienen una total transparencia. Únase a nosotros a este seminario informativo y así poder debatir esta nueva tendencia de regulaciones y aprender sobre lo que usted y sus proveedores deben hacer para prepararse de forma proactiva.
    ¿Qué conocerá?:
    - La auditoria sin previo aviso y el alcance de su valoración.
    - Quienes son los organismos notificadores y lo que van a pedir en una auditoria sin previo aviso.
    - Qué o quién es para la Comisión Europea un proveedor crítico.
    - Las preguntas que usted debería hacer a sus proveedores de materias primas sobre sus sistemas de gestión, cadena de suministro y calidad.
  • What you will learn about the AU5800 chemistry analyzer:
    - Typical performance observed.
    - Impact on the laboratory's turnaround time targets.
    - Operator feedback on instrument features.
    - Instrument uptime metrics.
  • Silver nanoparticles have extraordinary properties at the nanoscale, which are enabling a wave of innovative commercial products. Many of these new applications are in the field of bionanotechnology where the strong interaction between silver nanoparticles and specific wavelengths of light is utilized for applications such as sensing, imaging and therapeutics. This webinar will discuss the fundamentals of silver nanoparticle physics, the effect of the nanoparticle’s surface on the stability, dissolution, and transport of the nanoparticles in biological systems, and will describe both current and future biotechnology applications of silver nanoparticles.